{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:07:41Z","timestamp":1794665261277,"version":"4.9.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.beem.2024.101938","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T07:12:29Z","timestamp":1725693149000},"page":"101938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Overview of recent guidelines and consensus statements on initial screening and management of phaeochromocytoma and paraganglioma in SDHx pathogenic variant carriers and patients"],"prefix":"10.1016","volume":"39","author":[{"given":"Charlotte","family":"Lussey-Lepoutre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pacak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Amar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2024.101938_bib1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/jmedgenet-2018-105714","article-title":"Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma","volume":"56","author":"Ben Aim","year":"2019","journal-title":"J Med Genet"},{"key":"10.1016\/j.beem.2024.101938_bib2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/jmedgenet-2017-105127","article-title":"Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD","volume":"55","author":"Andrews","year":"2018","journal-title":"J Med Genet"},{"key":"10.1016\/j.beem.2024.101938_bib3","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1210\/jc.2012-2975","article-title":"Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators","volume":"98","author":"Gimenez-Roqueplo","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101938_bib4","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101938_bib5","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/jmedgenet-2020-107652","article-title":"International initiative for a curated SDHB variant database improving the diagnosis of hereditary paraganglioma and pheochromocytoma","volume":"59","author":"Ben Aim","year":"2022","journal-title":"J Med Genet"},{"key":"10.1016\/j.beem.2024.101938_bib6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.beem.2024.101938_bib7","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1373\/clinchem.2018.291369","article-title":"Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated O-methylated catecholamine metabolites","volume":"64","author":"Eisenhofer","year":"2018","journal-title":"Clin Chem"},{"key":"10.1016\/j.beem.2024.101938_bib8","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.beem.2024.101938_bib9","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1007\/s00330-015-4024-5","article-title":"The value of a rapid contrast-enhanced angio-MRI protocol in the detection of head and neck paragangliomas in SDHx mutations carriers: a retrospective study on behalf of the PGL.EVA investigators","volume":"26","author":"Gravel","year":"2016","journal-title":"Eur Radio"},{"key":"10.1016\/j.beem.2024.101938_bib10","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1158\/1078-0432.CCR-14-2751","article-title":"Superiority of [68Ga]-DOTATATE PET\/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma","volume":"21","author":"Janssen","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beem.2024.101938_bib11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00259-017-3896-9","article-title":"Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population","volume":"45","author":"Jha","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.beem.2024.101938_bib12","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/cen.14106","article-title":"Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis","volume":"91","author":"Satapathy","year":"2019","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2024.101938_bib13","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/ejendo\/lvad146","article-title":"Responses to systemic therapy in metastatic pheochromocytoma\/paraganglioma: a retrospective multicenter cohort study","volume":"189","author":"Fischer","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101938_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)02554-0","article-title":"Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial","author":"Baudin","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2024.101938_bib15","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J Hypertens"},{"key":"10.1016\/j.beem.2024.101938_bib16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41574-021-00492-3","article-title":"International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers","volume":"17","author":"Amar","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2024.101938_bib17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41574-023-00926-0","article-title":"Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert consensus statement","volume":"20","author":"Ta\u00efeb","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2024.101938_bib18","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S2213-8587(23)00038-4","article-title":"Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants","volume":"11","author":"Ta\u00efeb","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2024.101938_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/jmedgenet-2016-104297","article-title":"Risk assessment of maternally inherited SDHD paraganglioma and phaeochromocytoma","volume":"54","author":"Burnichon","year":"2017","journal-title":"J Med Genet"},{"key":"10.1016\/j.beem.2024.101938_bib20","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1126\/science.287.5454.848","article-title":"Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma","volume":"287","author":"Baysal","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.beem.2024.101938_bib21","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1086\/324413","article-title":"The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway","volume":"69","author":"Gimenez-Roqueplo","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.beem.2024.101938_bib22","doi-asserted-by":"crossref","first-page":"E214","DOI":"10.1210\/jc.2014-2138","article-title":"Genotype-specific differences in the tumor metabolite profile of pheochromocytoma and paraganglioma using untargeted and targeted metabolomics","volume":"100","author":"Rao","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101938_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007094","article-title":"The Warburg effect is genetically determined in inherited pheochromocytomas","volume":"4","author":"Favier","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.beem.2024.101938_bib24","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ccr.2013.04.018","article-title":"SDH mutations establish a hypermethylator phenotype in paraganglioma","volume":"23","author":"Letouz\u00e9","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beem.2024.101938_bib25","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1210\/jc.2005-1862","article-title":"Clinical presentation and penetrance of pheochromocytoma\/paraganglioma syndromes","volume":"91","author":"Benn","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101938_bib26","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00432-017-2397-3","article-title":"SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations","volume":"143","author":"Jochmanova","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.beem.2024.101938_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/cen.13877","article-title":"Can subunit-specific phenotypes guide surveillance imaging decisions in asymptomatic SDH mutation carriers?","volume":"90","author":"Tufton","year":"2019","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2024.101938_bib28","first-page":"5615","article-title":"Mutations in the SDHB gene are associated with extra-adrenal and\/or malignant phaeochromocytomas","volume":"63","author":"Gimenez-Roqueplo","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.beem.2024.101938_bib29","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1210\/jc.2018-02411","article-title":"Positive impact of genetic test on the management and outcome of patients with paraganglioma and\/or pheochromocytoma","volume":"104","author":"Buffet","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101938_bib30","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1016\/j.celrep.2020.03.022","article-title":"TET-mediated hypermethylation primes SDH-deficient cells for HIF2\u03b1-driven mesenchymal transition","volume":"30","author":"Morin","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.beem.2024.101938_bib31","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1158\/1078-0432.CCR-18-0139","article-title":"Telomerase activation and ATRX mutations are independent risk factors for metastatic pheochromocytoma and paraganglioma","volume":"25","author":"Job","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beem.2024.101938_bib32","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1158\/0008-5472.CAN-20-2936","article-title":"Loss of SDHB promotes dysregulated iron homeostasis, oxidative stress, and sensitivity to ascorbate","volume":"81","author":"Goncalves","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.beem.2024.101938_bib33","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41467-023-36769-6","article-title":"Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma","volume":"14","author":"Calsina","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.beem.2024.101938_bib34","first-page":"bnae005","article-title":"The immune landscape of pheochromocytoma and paraganglioma: current advances and perspectives","author":"Uher","year":"2024","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2024.101938_bib35","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1210\/jc.2016-1665","article-title":"A SDHC founder mutation causes paragangliomas (PGLs) in the French Canadians: new insights on the SDHC-related PGL","volume":"101","author":"Bourdeau","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101938_bib36","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1001\/jamaoncol.2017.0223","article-title":"Clinical characterization of the pheochromocytoma and paraganglioma susceptibility genes SDHA, TMEM127, MAX, and SDHAF2 for gene-informed prevention","volume":"3","author":"Bausch","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.beem.2024.101938_bib37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/jmedgenet-2021-108355","article-title":"UK recommendations for SDHA germline genetic testing and surveillance in clinical practice","volume":"60","author":"Hanson","year":"2023","journal-title":"J Med Genet"},{"key":"10.1016\/j.beem.2024.101938_bib38","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgae241","article-title":"Opposing effects of cannabidiol in patient-derived neuroendocrine tumor, pheochromocytoma\/paraganglioma primary cultures","author":"Wang","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101938_bib39","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1210\/endrev\/bnad011","article-title":"Biochemical assessment of pheochromocytoma and paraganglioma","volume":"44","author":"Eisenhofer","year":"2023","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2024.101938_bib40","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/jamaoto.2019.1110","article-title":"Characterization of malignant head and neck paragangliomas at a single institution across multiple decades","volume":"145","author":"McCrary","year":"2019","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.beem.2024.101938_bib41","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1210\/er.2014-1026","article-title":"Current approaches and recent developments in the management of head and neck paragangliomas","volume":"35","author":"Ta\u00efeb","year":"2014","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2024.101938_bib42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.beem.2024.101938_bib43","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1016\/S2589-7500(23)00094-8","article-title":"Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort","volume":"5","author":"Pamporaki","year":"2023","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.beem.2024.101938_bib44","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1210\/jc.2006-2315","article-title":"Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas","volume":"92","author":"Timmers","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101938_bib45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fonc.2019.00053","article-title":"Clinical, diagnostic, and treatment characteristics of SDHA-related metastatic pheochromocytoma and paraganglioma","volume":"9","author":"Jha","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.beem.2024.101938_bib46","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1530\/ERC-21-0359","article-title":"Head\/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine","volume":"29","author":"Richter","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101938_bib47","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beem.2024.101938_bib48","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European association of nuclear medicine practice guideline\/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Ta\u00efeb","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.beem.2024.101938_bib49","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/SLA.0000000000000283","article-title":"The presence of SDHB mutations should modify surgical indications for carotid body paragangliomas","volume":"260","author":"Ellis","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.beem.2024.101938_bib50","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S1470-2045(24)00133-5","article-title":"Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial","volume":"25","author":"Jimenez","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beem.2024.101938_bib51","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae061","article-title":"Anlotinib for metastatic progressed pheochromocytoma and paraganglioma: a retrospective study of real-world data","volume":"8","author":"Tian","year":"2024","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.beem.2024.101938_bib52","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12020-022-03218-1","article-title":"Immune signature of pheochromocytoma and paraganglioma in context of neuroendocrine neoplasms associated with prognosis","volume":"79","author":"Ghosal","year":"2023","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101938_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1021420","article-title":"Silent pheochromocytoma and paraganglioma: systematic review and proposed definitions for standardized terminology","volume":"13","author":"Constantinescu","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2024.101938_bib54","doi-asserted-by":"crossref","first-page":"e1301","DOI":"10.1210\/clinem\/dgaa888","article-title":"Screening of a large cohort of asymptomatic SDHx mutation carriers in routine practice","volume":"106","author":"Saie","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101938_bib55","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101938_bib56","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ando.2020.03.011","article-title":"Acute stress cardiomyopathy: heart of pheochromocytoma","volume":"82","author":"Cornu","year":"2021","journal-title":"Ann d\u2032Endocrinologie"},{"key":"10.1016\/j.beem.2024.101938_bib57","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2165\/00002018-200730110-00004","article-title":"Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management","volume":"30","author":"Eisenhofer","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.beem.2024.101938_bib58","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1210\/jc.2007-1720","article-title":"Preoperative management of the pheochromocytoma patient","volume":"92","author":"Pacak","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101938_bib59","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1245\/s10434-015-4519-y","article-title":"Hemodynamic stability during pheochromocytoma resection: lessons learned over the last two decades","volume":"22","author":"Livingstone","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.beem.2024.101938_bib60","article-title":"Efficacy of \u03b1-blockers on hemodynamic control during pheochromocytoma resection - a randomized controlled trial","author":"Buitenwerf","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101938_bib61","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1002\/bjs.11348","article-title":"Meta-analysis of \u03b1-blockade versus no blockade before adrenalectomy for phaeochromocytoma","volume":"107","author":"Schimmack","year":"2020","journal-title":"BJS Br J Surg"},{"key":"10.1016\/j.beem.2024.101938_bib62","doi-asserted-by":"crossref","first-page":"e2393","DOI":"10.1210\/clinem\/dgab130","article-title":"The role for metyrosine in the treatment of patients with pheochromocytoma and paraganglioma","volume":"106","author":"Gruber","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101938_bib63","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1210\/jc.2004-2025","article-title":"Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine","volume":"90","author":"Eisenhofer","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101938_bib64","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101938_bib65","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J Hypertens"},{"key":"10.1016\/j.beem.2024.101938_bib66","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/jmedgenet-2012-101192","article-title":"Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis","volume":"49","author":"van Hulsteijn","year":"2012","journal-title":"J Med Genet"},{"key":"10.1016\/j.beem.2024.101938_bib67","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1055\/s-0037-1604347","article-title":"Age and tumor volume predict growth of carotid and vagal body paragangliomas","volume":"78","author":"Heesterman","year":"2017","journal-title":"J Neurol Surg B Skull Base"},{"key":"10.1016\/j.beem.2024.101938_bib68","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41431-018-0116-4","article-title":"Clinical progression and metachronous paragangliomas in a large cohort of SDHD germline variant carriers","volume":"26","author":"Heesterman","year":"2018","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.beem.2024.101938_bib69","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/cen.13877","article-title":"Can subunit-specific phenotypes guide surveillance imaging decisions in asymptomatic SDH mutation carriers?","volume":"90","author":"Tufton","year":"2019","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2024.101938_bib70","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1210\/jc.2013-1907","article-title":"One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma","volume":"98","author":"Hescot","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101938_bib71","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2021.01.008","article-title":"Consensus on molecular imaging and theranostics in neuroendocrine neoplasms","volume":"146","author":"Ambrosini","year":"2021","journal-title":"Eur J Cancer"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24001143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24001143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T11:51:05Z","timestamp":1738324265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X24001143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1521690X24001143"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2024.101938","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overview of recent guidelines and consensus statements on initial screening and management of phaeochromocytoma and paraganglioma in SDHx pathogenic variant carriers and patients","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2024.101938","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101938"}}